Shelan, Mohamed http://orcid.org/0000-0002-6477-6655
Achard, Vérane
Appiagyei, Felix
Mose, Lucas http://orcid.org/0009-0006-0693-2716
Zilli, Thomas
Fankhauser, Christian D.
Zamboglou, Constantinos
Mohamad, Osama
Aebersold, Daniel M. http://orcid.org/0000-0002-9493-3834
Cathomas, Richard
Article History
Received: 19 December 2023
Revised: 27 March 2024
Accepted: 3 April 2024
First Online: 8 April 2024
Competing interests
: MS received honoraria and travel costs (institutional) from Janssen and Debiopharm, along with research grants from Debiopharm. Additionally, MS served on advisory boards for Astellas. VA served as a speaker for Janssen and Accor Healthcare and provided consultancy for Astellas. TZ disclosed receiving honoraria and travel costs (institutional) from Janssen, Amgen, Ferring, Debiopharm, Bayer, Astellas, Telix, and MVison, research grants from Varian Medical Systems, and advisory board roles with Janssen, Accord, and Astellas. RC declared an advisory role (institutional) with Astellas, Bayer, Janssen, Sanofi, Debiopharm, BMS, MSD, Roche, Novartis, Pfizer, Merck, and Ipsen, along with honoraria (institutional) from Astellas, Janssen, and Novartis. All other authors reported no competing interests.